Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.
Authors
Testoni, EwelinaStephenson, Natalie L
Torres-Ayuso, Pedro
Marusiak, Anna A
Trotter, Eleanor W
Hudson, Andrew M
Hodgkinson, Cassandra L
Morrow, Christopher J
Dive, Caroline
Brognard, John
Affiliation
Signalling Networks in Cancer Group, Cancer Research UK Manchester InstituteIssue Date
2016-01-12
Metadata
Show full item recordAbstract
The lack of actionable mutations in patients with non-small cell lung cancer (NSCLC) presents a significant hurdle in the design of targeted therapies for this disease. Here, we identify somatically mutated ABL1 as a genetic dependency that is required to maintain NSCLC cell survival. We demonstrate that NSCLC cells with ABL1 mutations are sensitive to ABL inhibitors and we verify that the drug-induced effects on cell viability are specific to pharmacological inhibition of the ABL1 kinase. Furthermore, we confirm that imatinib suppresses lung tumor growth in vivo, specifically in lung cancer cells harboring a gain-of-function (GOF) mutation in ABL1. Consistent with structural modeling, we demonstrate that mutations in ABL1 identified in primary NSCLC tumors and a lung cancer cell line increase downstream pathway activation compared to wild-type ABL1. Finally, we observe that the ABL1 cancer mutants display an increased cytosolic localization, which is associated with the oncogenic properties of the ABL1 kinase. In summary, our results suggest that NSCLC patients with ABL1 mutations could be stratified for treatment with imatinib in combination with other therapies.Citation
Somatically mutated ABL1 is an actionable and essential NSCLC survival gene. 2016: EMBO Mol MedJournal
EMBO Molecular MedicineDOI
10.15252/emmm.201505456PubMed ID
26758680Type
ArticleLanguage
enISSN
1757-4684ae974a485f413a2113503eed53cd6c53
10.15252/emmm.201505456
Scopus Count
Collections
Related articles
- Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase.
- Authors: Larocque EA, Naganna N, Opoku-Temeng C, Lambrecht AM, Sintim HO
- Issue date: 2018 Jun 20
- Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
- Authors: Rausch JL, Boichuk S, Ali AA, Patil SS, Liu L, Lee DM, Brown MF, Makielski KR, Liu Y, Taguchi T, Kuan SF, Duensing A
- Issue date: 2017 Jan 17
- Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.
- Authors: Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T
- Issue date: 2016 Apr 28
- Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR-203/ABL1 and circ 0051886/miR-637/ABL1.
- Authors: Lu YH, Huang ZY
- Issue date: 2021 Nov 15
- Novel ABL1 mutation in a Moroccan CML patient with Imatinib resistance.
- Authors: El Bouchikhi I, Azami Idrissi H, Lazraq A, El Makhzen B, Ahakoud M, Berrady R, Ouldim K, Bouguenouch L, El-Azami-El-Idrissi M
- Issue date: 2024 Nov